Your Health, We Care
Release date: 2026-07-17 16:57:55 Article From: Lucius Laos Recommended: 11
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operation for over five years. Its parent company can be traced back to Lucius Pharmaceutical Co., Ltd., founded in Hyderabad, India, in 2014.
Lucius Pharmaceutical is a legal pharmaceutical enterprise approved by the Lao government. The company is located in Thongmang Village, Xaythani District, Vientiane City, with a factory covering an area of approximately 210,000 square meters. It has built the Asia Pacific No.1 Smart Factory and introduced pharmaceutical equipment from China, the United States, Germany, and other countries. The company has obtained GMP (Good Manufacturing Practice) certification issued by the Lao Ministry of Health.
As of June 2024, Lucius Pharmaceutical has more than 200 generic drug varieties. Its products cover multiple therapeutic areas, including anti-tumor drugs, cardiovascular drugs, hematology drugs, diabetes drugs, dermatology drugs, men's health drugs, and anti-aging drugs.
In the field of anti-cancer drugs, the company has obtained marketing approvals for 54 anti-cancer drugs. Representative products include Sotorasib, Osimertinib, Cabozantinib, Larotrectinib, Lorlatinib, Ivosidenib, Gilteritinib, and many other targeted therapeutic drugs. In addition, the company has launched global first-generic products such as Revumenib.
Lucius Pharmaceutical has an annual generic drug production capacity exceeding 1.5 billion tablets. The company strictly organizes production in accordance with GMP standards and has established a full-process quality control system covering raw material procurement, production processes, and finished product inspection.
In October 2023, the World Health Organization (WHO) conducted a comprehensive assessment of Lucius Pharmaceutical's factory and confirmed that its facility fully complies with WHO standards. The company's production environment simultaneously meets GMP standards of Laos, the European Union, the United States, and China.
Lucius Pharmaceutical's business has expanded to multiple countries and regions, including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Turkey, Japan, and China. The company's products are mainly sold to markets in Southeast Asia, the Middle East, Eastern Europe, and Africa.
For patients with medication needs, it is recommended to obtain drugs through formal channels under the professional guidance of a licensed physician or pharmacist.
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended：12Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended：23Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended：36Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended：52Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended：75Release date: 2026-07-09
Laos's pharmaceutical industry started late and remains relatively small in scale; for a long time, domestic drug supply has relied on imports from China, India, and other coun···【more】
Recommended：82Release date: 2026-07-08
Before 2020, there were only a handful of legally approved local pharmaceutical manufacturers in Laos, mostly small state-owned factories with outdated equipment. Within just a few···【more】
Recommended：87Release date: 2026-07-07
With generic drugs as its core, Laos' pharmaceutical industry has formed an industrial pattern featuring coordination between state-owned and private enterprises as well as loc···【more】
Recommended：104Release date: 2026-07-02
The pharmaceutical industry in Laos started late and is limited in scale, with domestic drug supply long relying on imports of quality generic medicines from China, India and other···【more】
Recommended：1032Release date: 2026-07-01
Lucius Pharmaceuticals (Lao) Co., Ltd is a Lao pharmaceutical company established in 2020, headquartered in Vientiane, the capital of Laos. Despite its short history, the company h···【more】
Recommended：137Release date: 2026-06-30
The Lao generic pharmaceutical industry has developed rapidly in recent years, attracting increasing attention from patients worldwide. As one of the least developed countries in S···【more】
Recommended：292Release date: 2026-06-29
Laos; pharmaceutical industry is relatively limited in scale, and domestic drug supply has long relied on imports of high-quality generic medicines from countries such as China and···【more】
Recommended：112Release date: 2026-06-26
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended：783Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended：742Release date: 2024-07-09
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended：50Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended：79Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended：82Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended：98Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended：125Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended：234Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended：561Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination with abiraterone acetate (brand name: Akeega, Janssen Biotech, Inc.) plus predni···【more】
Recommended：506Release date: 2025-12-15
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplantation (HSCT) therapy for th···【more】
Recommended：534Release date: 2025-12-10
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, developed by Juno Therapeutics, a subsidiary of Bristol Myers Squibb) ···【more】
Recommended：514Release date: 2025-12-08
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for the treatment of adult patients with r···【more】
Recommended：587Release date: 2025-12-04
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 study showed that for patients with HER2-positive locally advanced or metastatic ···【more】
Recommended：461Release date: 2025-12-01
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
